PharmaEssentia Corporation (LUX:261280558)
Luxembourg
· Delayed Price · Currency is EUR · Price in USD 17.10
0.00 (0.00%)
At close: May 9, 2025
PharmaEssentia Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 11,339 | 9,735 | 5,106 | 2,882 | 656.51 | 557.26 | Upgrade
|
| Revenue Growth (YoY) | 93.12% | 90.67% | 77.15% | 339.00% | 17.81% | 82.29% | Upgrade
|
| Cost of Revenue | 1,347 | 1,177 | 610.54 | 812.29 | 378.86 | 373.32 | Upgrade
|
| Gross Profit | 9,992 | 8,558 | 4,495 | 2,070 | 277.65 | 183.93 | Upgrade
|
| Selling, General & Admin | 4,357 | 4,234 | 4,184 | 2,672 | 1,827 | 977.41 | Upgrade
|
| Research & Development | 2,811 | 2,588 | 2,224 | 1,426 | 1,273 | 922.38 | Upgrade
|
| Operating Expenses | 7,168 | 6,822 | 6,408 | 4,098 | 3,100 | 1,900 | Upgrade
|
| Operating Income | 2,824 | 1,736 | -1,913 | -2,028 | -2,822 | -1,716 | Upgrade
|
| Interest Expense | -22.48 | -22.19 | -46.69 | -18.53 | -9.97 | -8.26 | Upgrade
|
| Interest & Investment Income | 910.86 | 924.06 | 585.13 | 40.44 | 4.63 | 7.49 | Upgrade
|
| Currency Exchange Gain (Loss) | 429.12 | 376.38 | 375.7 | 122.36 | -1.85 | 9.82 | Upgrade
|
| Other Non Operating Income (Expenses) | -19.58 | -18.74 | 12.33 | 42.15 | 4.09 | -264.94 | Upgrade
|
| EBT Excluding Unusual Items | 4,122 | 2,996 | -986.93 | -1,842 | -2,826 | -1,972 | Upgrade
|
| Gain (Loss) on Sale of Assets | -1.18 | -0.93 | - | -0.1 | -0.07 | 0.02 | Upgrade
|
| Other Unusual Items | - | - | - | - | 14.59 | 23.71 | Upgrade
|
| Pretax Income | 4,121 | 2,995 | -986.93 | -1,842 | -2,811 | -1,948 | Upgrade
|
| Income Tax Expense | 221.86 | 29.15 | -363.1 | -467.06 | - | 0.13 | Upgrade
|
| Net Income | 3,899 | 2,966 | -623.84 | -1,375 | -2,811 | -1,948 | Upgrade
|
| Net Income to Common | 3,899 | 2,966 | -623.84 | -1,375 | -2,811 | -1,948 | Upgrade
|
| Shares Outstanding (Basic) | 332 | 331 | 322 | 284 | 260 | 242 | Upgrade
|
| Shares Outstanding (Diluted) | 334 | 334 | 322 | 284 | 260 | 242 | Upgrade
|
| Shares Change (YoY) | 1.10% | 3.59% | 13.47% | 9.24% | 7.39% | 10.55% | Upgrade
|
| EPS (Basic) | 11.76 | 8.96 | -1.93 | -4.84 | -10.80 | -8.04 | Upgrade
|
| EPS (Diluted) | 11.67 | 8.88 | -1.93 | -4.84 | -10.80 | -8.04 | Upgrade
|
| Free Cash Flow | 2,966 | 1,685 | -1,996 | -1,818 | -2,532 | -1,536 | Upgrade
|
| Free Cash Flow Per Share | 8.88 | 5.04 | -6.19 | -6.39 | -9.73 | -6.34 | Upgrade
|
| Dividend Per Share | 1.100 | 1.100 | - | - | - | - | Upgrade
|
| Gross Margin | 88.13% | 87.91% | 88.04% | 71.82% | 42.29% | 33.01% | Upgrade
|
| Operating Margin | 24.90% | 17.83% | -37.48% | -70.37% | -429.91% | -307.91% | Upgrade
|
| Profit Margin | 34.38% | 30.46% | -12.22% | -47.70% | -428.17% | -349.60% | Upgrade
|
| Free Cash Flow Margin | 26.16% | 17.31% | -39.09% | -63.06% | -385.74% | -275.72% | Upgrade
|
| EBITDA | 2,938 | 1,847 | -1,824 | -1,912 | -2,703 | -1,621 | Upgrade
|
| EBITDA Margin | 25.91% | 18.97% | -35.73% | -66.34% | - | -290.92% | Upgrade
|
| D&A For EBITDA | 114.09 | 110.52 | 89.24 | 116.28 | 119.59 | 94.7 | Upgrade
|
| EBIT | 2,824 | 1,736 | -1,913 | -2,028 | -2,822 | -1,716 | Upgrade
|
| EBIT Margin | 24.90% | 17.83% | -37.48% | -70.37% | - | - | Upgrade
|
| Effective Tax Rate | 5.38% | 0.97% | - | - | - | - | Upgrade
|
Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.